LEUPROLIDE ACETATE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Leuprolide Acetate Market, By Application (Prostate Cancer, Endometriosis, Uterine Fibroids, Central Precocious Puberty, Infertility, Hormone Therapy, and Others), By Product Form (Pre-filled Syringes, Vials, and Lyophilized Powder), By Route of Administration (Intramuscular, Subcutaneous, Intranasal, and Implantation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

In May 2024, Zydus Lifesciences and MSN Laboratories signed an exclusive licensing and supply agreement to introduce a generic version of Cabozantinib tablets (CABOMETYX) in the U.S. MSN Laboratories will produce the tablets, while Zydus will manage marketing, distribution, and sales. The partnership aims to improve patient access to this crucial medication at a lower cost.
In November 2022, Amneal Pharmaceuticals had received FDA approval for leuprolide acetate for injection. Harsher Singh, SVP of Amneal Biosciences, highlighted this as a significant advancement in its injectables portfolio, emphasizing its importance for the institutional market and its value as a complex new launch.
In November 2022, Cipla Limited and Cipla USA Inc. launched Leuprolide Acetate Injection Depot 22.5mg, approved by the U.S. FDA. This product is a single-dose injection for 3-month administration, used for the palliative treatment of advanced prostate cancer. It comes as lyophilized microspheres in a vial, with a prefilled syringe of mannitol solution and an easy-to-use MIXJECT transfer device.